Excerpt of panel discussion from symposium.
In summary, then, tazarotene is a selective RAR agonist. It has clinical efficacy similar to fluocinonide cream, but no risk of atrophogenicity, no tachyphylaxis, and longer duration of remission than we see with topical corticosteroids. Adverse effects are erythema, burning, and pruritus. Such effects are reduced and efficacy improved by combining the treatment with topical corticosteroids. It is also useful with ultraviolet B phototherapy. PUVA should be the next treatment modality to be explored in combination with tazarotene. It is useful on the scalp and in paronychial areas and, in fact, other areas that are refractory to other treatments your patients may be using. It is not photosensitizing so far, but more work needs to be done to prove that. It is pregnancy category X. If it is administered systemically, it is teratogenic. When administered topically, it is not. It is not lipophilic, so it is not stored in fat and is rapidly eliminated.
D000287:Administration, Topical; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011379:Prognosis; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome; D012176:Retinoids
D003879:Dermatologic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids